AC Immune SA (ACIU)

NGM – Real Time Price. Currency in USD

2.77

-0.06 (-2.12%)

At close: May 12, 2026, 4:00 PM EDT

2.82

+0.05 (1.81%)

After-hours: May 12, 2026, 5:33 PM EDT

30.04.2026

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune (ACIU) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.

30.04.2026

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today Amended Morphomer® Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer® small molecules Approaching multiple milestones including 12-month interim results of the AD3 cohort in ABATE in Q2 2026 and full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026 Cash resources of CHF 74.8 million as of March 31, 2026, provide funding into Q4 2027 Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today provided financial and corporate updates for the quarter ended March 31, 2026. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our anti-Abeta active immunotherapy and Tau aggregation inhibitor small molecules, respectively.

30.04.2026

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone payment Allows evaluation of potential for precision prevention of neurodegenerative diseases Data from ABATE Cohorts AD1, AD2 and AD3 after 12 months treatment expected Q2 2026 Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it dosed the first patients in Cohort AD4 in the ongoing Phase 1b/2 ABATE trial. As a result, AC Immune will receive a $12 million milestone payment from Takeda under the partners' exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24 for the treatment of Alzheimer's disease (AD).

09.04.2026

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.

09.04.2026

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.

07.04.2026

Why AC Immune Stock Zoomed Almost 15% Higher Today

This will help fund the biotech's development of a unique treatment for neurodegenerative diseases like Alzheimer's. The company could earn more than $2.1 billion if this work is successful.

07.04.2026

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer small molecules Investigational New Drug (IND)-enabling studies to commence in H1 2026 Lausanne, Switzerland, April 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced an agreement with Eli Lilly and Company (Lilly) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer® candidates and potential back-up compounds.

Videos

No Data

There is no data to display

Press releases

30.04.2026

AC Immune First Quarter 2026 Financial and Corporate Updates

30.04.2026

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

07.04.2026

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

13.03.2026

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's disease NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants dosed Approaching multiple value-inflection points, including interim results of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer's disease in H1 2026, and full 24-month data from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in Q3 2026 Cash resources of CHF 91.4 million as of December 31, 2025, provide funding to the end of Q3 2027 before any potential milestone payments Lausanne, Switzerland, March 13, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting α-synuclein.

AC Immune SA (ACIU)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AC Immune SA (ACIU)

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Why AC Immune Stock Zoomed Almost 15% Higher Today

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

Videos

No Data

Press releases

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Why AC Immune Stock Zoomed Almost 15% Higher Today

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

Videos

No Data

Press releases

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Search stocks

AC Immune SA (ACIU)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AC Immune SA (ACIU)

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Why AC Immune Stock Zoomed Almost 15% Higher Today

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

Videos

No Data

Press releases

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Why AC Immune Stock Zoomed Almost 15% Higher Today

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

Videos

No Data

Press releases

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update